- Britain medicine supplies stable but freight costs strain generic manufacturers
- Trade group warns shortages possible if Middle East conflict persists
- Low-margin generic drugs most exposed to rising transport costs
- Disruptions already affecting medicine supply routes and sensitive treatments
The availability of medicine resources to Britain might be strained in case the Middle East conflict continues, and the cost of freight is increased, threatening to make low-margin generic drugs, that are the most common prescription in National Health Service (NHS) and the industry at large, unsustainable, industry representatives said.
Medicines UK reported that the nation has not so far faced the problem of large-scale scarcity, but intense strain on supply chains is reducing the margin offered by any existing stocks. As the trade body that represents the manufacturers who make approximately 85 percent of NHS prescriptions in quantity, it signaled the growing dangers associated with transport delays and rise in shipping costs.
Reuters reports already that drugmakers are already picking up high logistics costs associated with rerouted deliveries and increasing delivery time. Although the situation is not yet severe due to the constant stability of supplies, industry officials affirm that the situation might worsen very fast in case the conflict interferes with the global trade routes.
According to Mark Samuels, chief executive of Medicines UK, "Britain is even a step closer to the potential shortage cases as the existing resilience is rather dependent on few inventories than on long-term supply conditions".
Generic Drugmakers Finished with Margins
The financial pressure is especially intense on producers of off-patent generic drugs that work on a thin margin and set the foundation of the NHS drugs provision. These are the products that are usually under 1 pound per month (or 1.34) of costs that they start their payments not even to take into consideration the increases in transportation costs.
"In the case the war is longer term, then I believe that manufacturers will no longer be able to cover the expenses and then we will either see a price increase to the NHS or we will have a supply break down". "Most likely both of them", Samuels said to Reuters.
The alert is indicative of a greater structural susceptibility of the pharmaceutical supply chain in which logistics expenses may constitute a significant portion of the overall cost of the cheap medicines. With the freight rates increasing, there is a possibility of supply disruptions as some products will become commercially unworkable.
It was reported on Reuters that shipping disruptions associated with the conflict have already impacted the circulation of vital medicines into some of the Gulf region. It has forced companies to make cargo flights rerouted and find overland solutions, which are making the transit process more expensive and lengthy.
More complicated Treatments at risk
More intricate drugs such as biosimilars are more vulnerable given that their production processes are longer, and they are more demanding to handle. Temperature-controlled logistics and long lead times frequently are a part of such treatments, thus being more susceptible to supply chain disruptions.
According to Samuels, although the standard oral medications can be relatively easier to control, biosimilars provide a weaker supply profile in the existing circumstances. Any delays or rise in costs in these areas may disproportionately affect the access of patients to the advanced therapies.
The larger pharmaceutical industry is also struggling with the energy market uncertainty in the global arena. Inflationary pressures along supply lines have been compounded by increasing fuel prices occasioned by interference in oil and gas export in the Middle East, which has tightened manufacturers.
Reuters suggested that the conflict has added new logistical pressures to different parts of the world, emphasizing how global medicine supply chains are all linked and susceptible to geopolitical shocks.
Stability of supply depends on the length of conflict
In spite of the increasing pressures, the supply of medicine in Britain is stable in the short run with stock piles and available procurement strategies. These measures however are temporary and inadequate in case the current conditions prevail as warned by the industry leaders.
The NHS will also have a hard time making decisions on whether to take in the increased cost or mitigate possible shortages by use of generic drugs that are cost-effective. The overall policy response to any sustained disruption might also be wider policy deliberations in the area of supply chain resilience and domestic production capacity.
According to market players, the scenario highlights why affordability and security of supply in the healthcare systems relying on global manufacturing and logistics chains are a delicate balance.
In the meantime, the overall situation of the continuation of the medicine flows indicates that the contingency measures are still holding, though the situation is still closely related to the situation in the Middle East war and its effects on world trade routes.
